Tandem Diabetes Care Inc reported results for the 2026 quarter with revenue of $254.56M, an improvement from $240.68M a year earlier, and a smaller net loss of ($21.17M) versus ($52.4M) in the prior-year quarter; diluted loss per share narrowed to ($0.31) from ($0.78).
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$254.56M$240.68M5.8% | Net income²($21.17M)($52.4M)59.6% | Diluted EPS³($0.31)($0.78)60.3% |
¹ Reported as “Sales”. ² Reported as “Net loss”. ³ Reported as “loss per share - basic and diluted”.
Business Highlights
- Revenue growth to $501.8M year-to-date (from $475.1M) was driven by higher pump volumes and improved pricing.
- A shift toward a pharmacy pay-as-you-go channel reduced pump average selling prices but increased supply pricing and recurring revenue.
- Brand momentum included roughly 63,000 pumps shipped year-to-date and rollout of Control‑IQ+ supported by published clinical data.
- Supply constraints from a key infusion set supplier limited volumes and affected inventory levels.
- Product development progress: FDA 510(k) submission for Mobi tubeless capability; pipeline includes a next‑generation patch and extended‑wear technology.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.